메뉴 건너뛰기




Volumn 17, Issue 1, 2018, Pages

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): A randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

(17)  Rosenstock, Julio a   Perkovic, Vlado b   Alexander, John H c   Cooper, Mark E d   Marx, Nikolaus e   Pencina, Michael J c   Toto, Robert D f   Wanner, Christoph g   Zinman, Bernard h,i   Baanstra, David j   Pfarr, Egon j   Mattheus, Michaela j   Broedl, Uli C j   Woerle, Hans Juergen k   George, Jyothis T j   von Eynatten, Maximilian j   McGuire, Darren K l  


Author keywords

Cardiovascular diseases; Clinical trial, phase IV; Diabetes mellitus, type 2; Diabetic nephropathies; Dipeptidyl peptidase IV inhibitors; Linagliptin; Research design; Treatment outcome

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LINAGLIPTIN; METFORMIN; PLACEBO; SULFONYLUREA; BIOLOGICAL MARKER; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

EID: 85043768158     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-018-0682-3     Document Type: Article
Times cited : (68)

References (54)
  • 1
    • 34250212715 scopus 로고    scopus 로고
    • Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
    • Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-71.
    • (2007) N Engl J Med , vol.356 , Issue.24 , pp. 2457-2471
    • Nissen, S.E.1    Wolski, K.2
  • 2
    • 28144451163 scopus 로고    scopus 로고
    • Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus
    • Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005;294(20):2581-6.
    • (2005) JAMA , vol.294 , Issue.20 , pp. 2581-2586
    • Nissen, S.E.1    Wolski, K.2    Topol, E.J.3
  • 3
    • 72249116214 scopus 로고    scopus 로고
    • Silver Spring, MD, U.S. Food and Drug Administration; Accessed 10 July 2017.
    • Center for Drug Evaluation and Research. Guidance for industry. Diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring, MD, U.S. Food and Drug Administration; 2008. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf. Accessed 10 July 2017.
    • (2008) Diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes.
  • 5
    • 84964703072 scopus 로고    scopus 로고
    • Evaluating the cardiovascular safety of new medications for type 2 diabetes: time to reassess?
    • Smith RJ, Goldfine AB, Hiatt WR. Evaluating the cardiovascular safety of new medications for type 2 diabetes: time to reassess? Diabetes Care. 2016;39(5):738-42.
    • (2016) Diabetes Care , vol.39 , Issue.5 , pp. 738-742
    • Smith, R.J.1    Goldfine, A.B.2    Hiatt, W.R.3
  • 16
    • 85029216639 scopus 로고    scopus 로고
    • Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCAIT): a randomised, multicentre trial
    • Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, Rivellese AA, Squatrito S, Giorda CB, Sesti G, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCAIT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017;5(11):887-97.
    • (2017) Lancet Diabetes Endocrinol. , vol.5 , Issue.11 , pp. 887-897
    • Vaccaro, O.1    Masulli, M.2    Nicolucci, A.3    Bonora, E.4    Del Prato, S.5    Maggioni, A.P.6    Rivellese, A.A.7    Squatrito, S.8    Giorda, C.B.9    Sesti, G.10
  • 17
    • 84946761555 scopus 로고    scopus 로고
    • Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
    • Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 2016;12(2):73-81.
    • (2016) Nat Rev Nephrol. , vol.12 , Issue.2 , pp. 73-81
    • Thomas, M.C.1    Cooper, M.E.2    Zimmet, P.3
  • 20
    • 85024388262 scopus 로고    scopus 로고
    • Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference
    • Baigent C, Herrington WG, Coresh J, Landray MJ, Levin A, Perkovic V, Pfeffer MA, Rossing P, Walsh M, Wanner C, et al. Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2017;92(2):297-305.
    • (2017) Kidney Int , vol.92 , Issue.2 , pp. 297-305
    • Baigent, C.1    Herrington, W.G.2    Coresh, J.3    Landray, M.J.4    Levin, A.5    Perkovic, V.6    Pfeffer, M.A.7    Rossing, P.8    Walsh, M.9    Wanner, C.10
  • 21
    • 84873359828 scopus 로고    scopus 로고
    • Kidney disease and increased mortality risk in type 2 diabetes
    • Afkarian M, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24:302-8.
    • (2013) J Am Soc Nephrol , vol.24 , pp. 302-308
    • Afkarian, M.1
  • 22
    • 85006282748 scopus 로고    scopus 로고
    • An update on DPP-4 inhibitors in the management of type 2 diabetes
    • Cahn A, Cernea S, Raz I. An update on DPP-4 inhibitors in the management of type 2 diabetes. Expert Opin Emerg Drugs. 2016;21(4):409-19.
    • (2016) Expert Opin Emerg Drugs. , vol.21 , Issue.4 , pp. 409-419
    • Cahn, A.1    Cernea, S.2    Raz, I.3
  • 23
    • 84930085787 scopus 로고    scopus 로고
    • Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
    • Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067-76.
    • (2015) Lancet , vol.385 , Issue.9982 , pp. 2067-2076
    • Zannad, F.1    Cannon, C.P.2    Cushman, W.C.3    Bakris, G.L.4    Menon, V.5    Perez, A.T.6    Fleck, P.R.7    Mehta, C.R.8    Kupfer, S.9    Wilson, C.10
  • 24
    • 85021438535 scopus 로고    scopus 로고
    • Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial
    • McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, Bethel MA, Cornel JH, Lopes RD, Halvorsen S, et al. Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. JAMA Cardiol. 2016;1(2):126-35.
    • (2016) JAMA Cardiol , vol.1 , Issue.2 , pp. 126-135
    • McGuire, D.K.1    Werf, F.2    Armstrong, P.W.3    Standl, E.4    Koglin, J.5    Green, J.B.6    Bethel, M.A.7    Cornel, J.H.8    Lopes, R.D.9    Halvorsen, S.10
  • 25
    • 77950197593 scopus 로고    scopus 로고
    • The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans
    • Blech S, Ludwig-Schwellinger E, Grafe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos. 2010;38(4):667-78.
    • (2010) Drug Metab Dispos , vol.38 , Issue.4 , pp. 667-678
    • Blech, S.1    Ludwig-Schwellinger, E.2    Grafe-Mody, E.U.3    Withopf, B.4    Wagner, K.5
  • 27
    • 84931264841 scopus 로고    scopus 로고
    • Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events
    • Rosenstock J, Marx N, Neubacher D, Seck T, Patel S, Woerle HJ, Johansen OE. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol. 2015;14:57.
    • (2015) Cardiovasc Diabetol. , vol.14 , pp. 57
    • Rosenstock, J.1    Marx, N.2    Neubacher, D.3    Seck, T.4    Patel, S.5    Woerle, H.J.6    Johansen, O.E.7
  • 28
    • 84939565970 scopus 로고    scopus 로고
    • Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes
    • Cooper ME, Perkovic V, McGill JB, Groop PH, Wanner C, Rosenstock J, Hehnke U, Woerle HJ, von Eynatten M. Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes. Am J Kidney Dis. 2015;66(3):441-9.
    • (2015) Am J Kidney Dis , vol.66 , Issue.3 , pp. 441-449
    • Cooper, M.E.1    Perkovic, V.2    McGill, J.B.3    Groop, P.H.4    Wanner, C.5    Rosenstock, J.6    Hehnke, U.7    Woerle, H.J.8    Eynatten, M.9
  • 29
    • 85028091172 scopus 로고    scopus 로고
    • Composite primary end points in cardiovascular outcomes trials involving type 2 diabetes patients: should unstable angina be included in the primary end point?
    • Marx N, McGuire DK, Perkovic V, Woerle HJ, Broedl UC, von Eynatten M, George JT, Rosenstock J. Composite primary end points in cardiovascular outcomes trials involving type 2 diabetes patients: should unstable angina be included in the primary end point? Diabetes Care. 2017;40(9):1144-51.
    • (2017) Diabetes Care , vol.40 , Issue.9 , pp. 1144-1151
    • Marx, N.1    McGuire, D.K.2    Perkovic, V.3    Woerle, H.J.4    Broedl, U.C.5    Eynatten, M.6    George, J.T.7    Rosenstock, J.8
  • 30
    • 85043753792 scopus 로고    scopus 로고
    • Meeting expectations to exclude a CV risk margin of 1.3.
    • Accessed 24 Oct 2017.
    • Center for Drug Evaluation and Research. Meeting expectations to exclude a CV risk margin of 1.3. In: Application number: 204042Orig1s000 summary review. 2013, p. 20. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000SumR.pdf. Accessed 24 Oct 2017.
    • (2013) Application number: 204042Orig1s000 summary review. , pp. 20
  • 31
    • 84911459484 scopus 로고    scopus 로고
    • GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration
    • Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, de Zeeuw D, Cheung AK, Coresh J. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014;64(6):821-35.
    • (2014) Am J Kidney Dis , vol.64 , Issue.6 , pp. 821-835
    • Levey, A.S.1    Inker, L.A.2    Matsushita, K.3    Greene, T.4    Willis, K.5    Lewis, E.6    Zeeuw, D.7    Cheung, A.K.8    Coresh, J.9
  • 32
    • 84910607379 scopus 로고    scopus 로고
    • GFR decline as an end point in trials of CKD: a viewpoint from the FDA
    • Thompson A, Lawrence J, Stockbridge N. GFR decline as an end point in trials of CKD: a viewpoint from the FDA. Am J Kidney Dis. 2014;64(6):836-7.
    • (2014) Am J Kidney Dis , vol.64 , Issue.6 , pp. 836-837
    • Thompson, A.1    Lawrence, J.2    Stockbridge, N.3
  • 33
    • 84910666073 scopus 로고    scopus 로고
    • GFR decline as an end point for clinical trials in CKD: a view from Europe
    • Mol PG, Maciulaitis R, Vetter T. GFR decline as an end point for clinical trials in CKD: a view from Europe. Am J Kidney Dis. 2014;64(6):838-40.
    • (2014) Am J Kidney Dis , vol.64 , Issue.6 , pp. 838-840
    • Mol, P.G.1    Maciulaitis, R.2    Vetter, T.3
  • 36
    • 85010190524 scopus 로고    scopus 로고
    • A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes
    • Jax T, Stirban A, Terjung A, Esmaeili H, Berk A, Thiemann S, Chilton R, von Eynatten M, Marx N. A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes. Cardiovasc Diabetol. 2017;16(1):13.
    • (2017) Cardiovasc Diabetol. , vol.16 , Issue.1 , pp. 13
    • Jax, T.1    Stirban, A.2    Terjung, A.3    Esmaeili, H.4    Berk, A.5    Thiemann, S.6    Chilton, R.7    Eynatten, M.8    Marx, N.9
  • 40
    • 84959419888 scopus 로고    scopus 로고
    • Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study
    • Ou HT, Chang KC, Li CY, Wu JS. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study. Cardiovasc Diabetol. 2016;15:41.
    • (2016) Cardiovasc Diabetol. , vol.15 , pp. 41
    • Ou, H.T.1    Chang, K.C.2    Li, C.Y.3    Wu, J.S.4
  • 41
    • 85030443374 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 inhibitors and risk of heart failure in patients with type 2 diabetes mellitus: a population-based cohort study
    • Kim YG, Yoon D, Park S, Han SJ, Kim DJ, Lee KW, Park RW, Kim HJ. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in patients with type 2 diabetes mellitus: a population-based cohort study. Circ Heart Fail. 2017;10(9):e003957.
    • (2017) Circ Heart Fail. , vol.10 , Issue.9
    • Kim, Y.G.1    Yoon, D.2    Park, S.3    Han, S.J.4    Kim, D.J.5    Lee, K.W.6    Park, R.W.7    Kim, H.J.8
  • 43
    • 85013890365 scopus 로고    scopus 로고
    • Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial
    • Neal B, Perkovic V, Matthews DR, Mahaffey KW, Fulcher G, Meininger G, Erondu N, Desai M, Shaw W, Vercruysse F, et al. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial. Diabetes Obes Metab. 2017;19(3):387-93.
    • (2017) Diabetes Obes Metab , vol.19 , Issue.3 , pp. 387-393
    • Neal, B.1    Perkovic, V.2    Matthews, D.R.3    Mahaffey, K.W.4    Fulcher, G.5    Meininger, G.6    Erondu, N.7    Desai, M.8    Shaw, W.9    Vercruysse, F.10
  • 44
    • 84880924263 scopus 로고    scopus 로고
    • Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-a randomized placebo-controlled trial
    • Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Stein P, Desai M, Shaw W, Jiang J, Vercruysse F, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-a randomized placebo-controlled trial. Am Heart J. 2013;166(2):217-23.
    • (2013) Am Heart J. , vol.166 , Issue.2 , pp. 217-223
    • Neal, B.1    Perkovic, V.2    Zeeuw, D.3    Mahaffey, K.W.4    Fulcher, G.5    Stein, P.6    Desai, M.7    Shaw, W.8    Jiang, J.9    Vercruysse, F.10
  • 45
    • 85020459778 scopus 로고    scopus 로고
    • EMPA-REG OUTCOME: the nephrologist's point of view
    • Wanner C. EMPA-REG OUTCOME: the nephrologist's point of view. Am J Cardiol. 2017;120(1S):S59-67.
    • (2017) Am J Cardiol , vol.120 , Issue.1 , pp. S59-S67
    • Wanner, C.1
  • 47
    • 84890476805 scopus 로고    scopus 로고
    • Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction
    • Groop PH, Cooper ME, Perkovic V, Emser A, Woerle HJ, von Eynatten M. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care. 2013;36(11):3460-8.
    • (2013) Diabetes Care , vol.36 , Issue.11 , pp. 3460-3468
    • Groop, P.H.1    Cooper, M.E.2    Perkovic, V.3    Emser, A.4    Woerle, H.J.5    Eynatten, M.6
  • 51
    • 84964689544 scopus 로고    scopus 로고
    • The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy
    • Tsuprykov O, Ando R, Reichetzeder C, von Websky K, Antonenko V, Sharkovska Y, Chaykovska L, Rahnenfuhrer J, Hasan AA, Tammen H, et al. The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy. Kidney Int. 2016;89(5):1049-61.
    • (2016) Kidney Int , vol.89 , Issue.5 , pp. 1049-1061
    • Tsuprykov, O.1    Ando, R.2    Reichetzeder, C.3    Websky, K.4    Antonenko, V.5    Sharkovska, Y.6    Chaykovska, L.7    Rahnenfuhrer, J.8    Hasan, A.A.9    Tammen, H.10
  • 52
    • 84951041234 scopus 로고    scopus 로고
    • Linagliptin limits high glucose induced conversion of latent to active TGFss through interaction with CIM6PR and limits renal tubulointerstitial fibronectin
    • Gangadharan Komala M, Gross S, Zaky A, Pollock C, Panchapakesan U. Linagliptin limits high glucose induced conversion of latent to active TGFss through interaction with CIM6PR and limits renal tubulointerstitial fibronectin. PLoS ONE. 2015;10(10):e0141143.
    • (2015) PLoS ONE , vol.10 , Issue.10
    • Gangadharan Komala, M.1    Gross, S.2    Zaky, A.3    Pollock, C.4    Panchapakesan, U.5
  • 54
    • 84901309585 scopus 로고    scopus 로고
    • Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen
    • Kanasaki K, Shi S, Kanasaki M, He J, Nagai T, Nakamura Y, Ishigaki Y, Kitada M, Srivastava SP, Koya D. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes. 2014;63(6):2120-31.
    • (2014) Diabetes , vol.63 , Issue.6 , pp. 2120-2131
    • Kanasaki, K.1    Shi, S.2    Kanasaki, M.3    He, J.4    Nagai, T.5    Nakamura, Y.6    Ishigaki, Y.7    Kitada, M.8    Srivastava, S.P.9    Koya, D.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.